Comparison of three modalities of plasmapheresis on coagulation: Centrifugal, single-membrane filtration, and double-filtration plasmapheresis.
ABO-incompatible kidney transplantation
cTPE
clotting factors
coagulation
double-filtration plasmapheresis (DFPP)
mTPE
plasmapheresis
thrombin generation
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
13
01
2021
received:
21
09
2020
accepted:
14
01
2021
pubmed:
29
1
2021
medline:
15
12
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
Plasmapheresis can deplete pathogenic antibodies and allow ABO- and/or HLA-incompatible transplantation. To determine the impacts of three modalities of plasmapheresis (centrifugal plasmapheresis [cTPE], single-filtration plasmapheresis [mTPE], double-filtration plasmapheresis [DFPP]) on hemostasis parameters and thrombin generation. Prospective, comparative study on 21 patients that received three modalities of plasmapheresis (7 patients/group). Hemostasis (prothrombin time [PT], activated partial thromboplastin time [aPTT], procoagulant factors and natural anticoagulants) were measured before and after the first plasmapheresis session. Thrombin generation was also assessed in platelet-poor plasma using an STA-Genesia (Stago) analyzer and Thromboscreen reagents (Stago) in 4-5 patients from each group. Both cTPE and mTPE resulted in high decreases in proteins, whatever their molecular weights. Median post/pre ratios were 0.27 to 0.55 for cTPE for most proteins (except FVIII [0.64] and VWF [0.57]). Median post/pre-ratios of mTPE were 0.28 to 0.56 for all proteins. DFPP decreased high-molecular-weight proteins (fibrinogen, FV, FVIII, FXI, VWF) and proteins strongly bound to large molecules (protein SandTFPI). Median post/pre ratios with cTPE and mTPE were similar to DFPP for fibrinogen and FXIII. Regarding thrombin generation, cTPE and mTPE did not significantly modify endogenous thrombin potential (ETP) and DFPP induced a slight decrease in ETP (median post/pre ratio at 0.73) in the absence of thrombomodulin. ETP inhibition by thrombomodulin was decreased for all procedures. DFPP depleted high molecular-weight proteins in contrast to cTPE and mTPE, which significantly decreased all proteins. Regarding thrombin generation, depletion of procoagulant factors was counterbalanced by a decrease in some natural anticoagulants whatever plasmapheresis method used; with all methods, fibrinogen and FXIII were highly depleted.
Sections du résumé
BACKGROUND
BACKGROUND
Plasmapheresis can deplete pathogenic antibodies and allow ABO- and/or HLA-incompatible transplantation.
AIM
OBJECTIVE
To determine the impacts of three modalities of plasmapheresis (centrifugal plasmapheresis [cTPE], single-filtration plasmapheresis [mTPE], double-filtration plasmapheresis [DFPP]) on hemostasis parameters and thrombin generation.
MATERIALS/METHODS
METHODS
Prospective, comparative study on 21 patients that received three modalities of plasmapheresis (7 patients/group). Hemostasis (prothrombin time [PT], activated partial thromboplastin time [aPTT], procoagulant factors and natural anticoagulants) were measured before and after the first plasmapheresis session. Thrombin generation was also assessed in platelet-poor plasma using an STA-Genesia (Stago) analyzer and Thromboscreen reagents (Stago) in 4-5 patients from each group.
RESULTS
RESULTS
Both cTPE and mTPE resulted in high decreases in proteins, whatever their molecular weights. Median post/pre ratios were 0.27 to 0.55 for cTPE for most proteins (except FVIII [0.64] and VWF [0.57]). Median post/pre-ratios of mTPE were 0.28 to 0.56 for all proteins. DFPP decreased high-molecular-weight proteins (fibrinogen, FV, FVIII, FXI, VWF) and proteins strongly bound to large molecules (protein SandTFPI). Median post/pre ratios with cTPE and mTPE were similar to DFPP for fibrinogen and FXIII. Regarding thrombin generation, cTPE and mTPE did not significantly modify endogenous thrombin potential (ETP) and DFPP induced a slight decrease in ETP (median post/pre ratio at 0.73) in the absence of thrombomodulin. ETP inhibition by thrombomodulin was decreased for all procedures.
CONCLUSIONS
CONCLUSIONS
DFPP depleted high molecular-weight proteins in contrast to cTPE and mTPE, which significantly decreased all proteins. Regarding thrombin generation, depletion of procoagulant factors was counterbalanced by a decrease in some natural anticoagulants whatever plasmapheresis method used; with all methods, fibrinogen and FXIII were highly depleted.
Substances chimiques
Hemoglobins
0
Thrombin
EC 3.4.21.5
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
408-419Subventions
Organisme : Terumo BCT
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Ahmadpoor P, Aglae C, Cariou S, et al. Physiological role of plasma and its components and the clinical implications of different methods of apheresis: a narrative review. Ther Apher Dial. 2020;1-11. https://doi.org/10.1111/1744-9987.13567 PMID: 32710797.
Zanatta E, Cozzi M, Marson P, Cozzi F. The role of plasma exchange in the management of autoimmune disorders. Br J Haematol. 2019;186(2):207-219.
Hafer C, Golla P, Gericke M, et al. Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int Urol Nephrol. 2016;48(1):133-138.
Zöllner S, Pablik E, Druml W, Derfler K, Rees A, Biesenbach P. Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two. Blood Purif. 2014;38(2):160-166.
Zantek ND, Morgan S, Zantek PF, Mair DC, Bowman RJ, Aysola A. Effect of therapeutic plasma exchange on coagulation parameters in patients on warfarin. J Clin Apheresis. 2014;29(2):75-82.
Vatazin AV, Zulkarnaev AB. The impact of therapeutic plasma exchange and double filtration plasmapheresis on hemostasis in renal transplant recipients. Ter Arkh. 2018;90(6):22-27.
Jouve T, Marlu R, Malvezzi P, et al. Reducing fibrinogen and factor XIII using double-filtration plasmapheresis for antibody-mediated rejection: predictive models. Blood Purif. 2018;46(3):239-245.
Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007;84(12 suppl):S30-S32.
Cheng L, Tang Y-Q, Yi J, et al. Double filtration plasmapheresis in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis with severe kidney dysfunction. Blood Purif. 2020;49(6):713-722.
Xing Y, Wang S, Liu C, et al. Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatoid arthritis: a retrospective cohort study. Medicine (Baltimore). 2020;99(28):e20966.
Kaplan AA. Therapeutic plasma exchange: a technical and operational review. J Clin Apheresis. 2013;28(1):3-10.
Feng D, Stafford KA, Broze GJ, Stafford DW. Evidence of clinically significant extravascular stores of factor IX. J Thromb Haemost. 2013;11(12):2176-2178.
Koessler J, Kobsar A, Kuhn S, et al. The effect of immunoadsorption with the Immusorba TR-350 column on coagulation compared to plasma exchange. Vox Sang. 2015;108(1):46-51.
Marlu R, Malvezzi P, Seyve L, et al. Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation. Thromb Res. 2018;166:113-121.
Hanafusa N, Kondo Y, Suzuki M, Nakao A, Noiri E, Fujita T. Double filtration plasmapheresis can decrease factor XIII activity. Ther Apher Dial. 2007;11(3):165-170.
Kes P, Janssens ME, Bašić-Jukić N, Kljak M. A randomized crossover study comparing membrane and centrifugal therapeutic plasma exchange procedures. Transfusion. 2016;56(12):3065-3072.
Casini A, de Moerloose P. Congenital fibrinogen disorders group. Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia. 2016;22(6):898-905. https://doi.org/10.1111/hae.13061 PMID: 27640400.
Spahn DR, Spahn GH, Stein P. Indications and risks of fibrinogen in surgery and trauma. Semin Thromb Hemost. 2016;42(2):147-154.
Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2014;54(5):1389-1405.quiz 1388.
Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders. J Thromb Haemost. 2012;10(4):615-621.
Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125(13):2052-2061.
Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned? Blood Rev. 2012;26(5):197-203.
Duchemin J, Pittet JL, Tartary M, et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost. 1994;71(3):331-338.
Yamada C, Pipe SW, Zhao L, et al. Coagulation status after therapeutic plasma exchange using citrate in kidney transplant recipients. Transfusion. 2016;56(12):3073-3080. https://doi.org/10.1111/trf.13803.